PapersPMID:41459382
Safety assessment and gastrointestinal tolerance of a novel highly bioavailable turmeric extract formulation: A randomised, double-blind, placebo controlled clinical trial.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“No statistically significant differences in mean daily scores for bloating, stomach noises, flatulence, stool frequency, or stool consistency were observed between groups provided TF or placebo at the end of the study (Table 1).”
- Study
- RCT
- Duration
- 5 weeks
- Dose studied
- 1000 mg/day (four 250 mg capsules once daily before breakfast) for 35 consecutive days
- Population
- Healthy adults aged 18 to 60 years, 60 randomised (30 per arm), 5-week parallel trial against maltodextrin placebo
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Healthy adults aged 18 to 60 years; 60 enrolled, 30 per group; dosed a novel turmeric extract formulation (TF, Turmipure Gold, dried colloidal system standardised to > 30 % curcuminoids, composed of turmeric extract, acacia gum, sunflower oil and quillaia extract), 1000 mg once daily for 35 days versus maltodextrin placebo
- Participants
- 60
- Comparator
- placebo
- Duration
- 35 days
- Endpoints measured
- 39